Morgan Stanley analyst Erin Wright raised the firm’s price target on Elevance Health (ELV) to $359 from $316 and keeps an Equal Weight rating on the shares. Last week’s Stars results were “encouraging” for the sector and Managed Care Organization sentiment has “improved slightly,” but there is “still a lot to prove” as the focus turns to utilization and early reads on 2026, the analyst tells investors in a Q3 earnings preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health initiated with a Neutral at Goldman Sachs
- Clover Health ‘loses big’ in CMS star ratings, says Leerink
- Elevance Health price target raised to $370 from $330 at BofA
- Elevance Health price target raised to $420 from $342 at Mizuho
- Elevance Health price target raised to $395 from $373 at Barclays